Neurogene
NGNE
25.87
+0.42
+1.65%
Neurogene
US · NGNE
#3726 by market cap
25.87
+0.42
+1.65%
Live - 5344 symbols - heartbeat 303s ago
· 2026-10-08 09:19
Pre-market
29.12
+12.56%
After-hours
25.87
0.00%
Overnight
26.11
+0.93%
- Market cap
- 517.69M
- P/E (TTM)i
- -5.13
- P/Bi
- 2.38
- EPSi
- -4.24
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on NGNE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 11.27, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Latest year -100.00% YoY
Margins
Key ratios & quality
- Altman Z-Scorei
- 11.27
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 925.00K | 0 |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.27M | 9.01M | 11.19M | 22.61M | 28.32M |
| Research & development | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M |
| Operating profit | -50.53M | -56.52M | -55.58M | -82.61M | -103.33M |
| Pretax profit | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
| Tax | -- | -- | -- | -- | -- |
| Net profit | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
| Basic EPS | -35 | -38 | -74 | -4 | -4 |
| Diluted EPS | -34.60 | -37.80 | -73.84 | -4.28 | -4.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | -- | 0 | 0 | 0 | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.16M | 6.72M | 6.56M | 6.89M | 8.20M | 11.20M |
| Research & development | 17.76M | 19.37M | 17.24M | 20.64M | 25.15M | 25.47M |
| Operating profit | -25.92M | -26.08M | -23.80M | -27.53M | -33.35M | -36.67M |
| Pretax profit | -22.65M | -22.02M | -20.95M | -24.74M | -30.93M | -34.49M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -22.65M | -22.02M | -20.95M | -24.74M | -30.93M | -34.49M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -2 |
| Diluted EPS | -1.08 | -1.05 | -0.99 | -1.13 | -1.39 | -1.53 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 73.96M | 84.72M | 200.35M | 315.92M | 271.77M |
| Cash & ST investments | 70.54M | 82.02M | 197.16M | 312.41M | 269.01M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | 101.49M | 109.27M | 222.57M | 335.73M | 288.60M |
| Total current liabilities | 10.86M | 6.65M | 22.97M | 15.16M | 16.41M |
| Short-term debt | 610.00K | 702.00K | 2.88M | 4.09M | 3.70M |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 193,362,000.00 | 255,004,000.00 | 36,549,000.00 | 25,355,000.00 | 23,717,000.00 |
| Total equity | -91.88M | -145.74M | 186.02M | 310.38M | 264.89M |
| Retained earnings | -95.65M | -150.84M | -187.15M | -262.30M | -352.65M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 296.40M | 278.99M | 270.52M | 271.77M | 246.75M | 228.91M |
| Cash & ST investments | 292.60M | 274.52M | 265.41M | 269.01M | 243.18M | 225.39M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 315.30M | 297.32M | 287.83M | 288.60M | 263.14M | 244.36M |
| Total current liabilities | 14.09M | 15.44M | 14.71M | 16.41M | 18.87M | 21.51M |
| Short-term debt | 4.18M | 4.28M | 3.74M | 3.70M | 3.05M | 3.03M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 23,506,000.00 | 24,061,000.00 | 22,292,000.00 | 23,717,000.00 | 25,358,000.00 | 27,231,000.00 |
| Total equity | 291.80M | 273.26M | 265.54M | 264.89M | 237.78M | 217.13M |
| Retained earnings | -284.95M | -306.96M | -327.91M | -352.65M | -383.58M | -418.07M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -46.40M | -52.82M | -51.42M | -70.60M | -77.17M |
| Depreciation & amortization | 947.00K | 3.20M | 3.30M | 3.25M | 3.09M |
| Free cash flow | -64.77M | -55.05M | -51.74M | -71.41M | -78.36M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 92.34M | 189.59M | 30.38M |
| Ending cash balance | 70.54M | 82.02M | 148.72M | 136.93M | 104.18M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -20.77M | -19.46M | -19.51M | -17.43M | -26.12M | -23.76M |
| Depreciation & amortization | 762.00K | 767.00K | 776.00K | 787.00K | 854.00K | 820.00K |
| Free cash flow | -21.55M | -19.61M | -19.64M | -17.56M | -26.40M | -24.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 9.80M | 20.58M | -- | -- |
| Ending cash balance | 71.11M | 59.15M | 71.34M | 104.18M | 124.50M | 112.82M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -180.30 | -30.28 | -31.41 |
| ROA %i | -49.78 | -52.37 | -21.89 | -26.92 | -28.94 |
| ROIC %i | -- | -- | -128.23 | -31.73 | -33.94 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -8,122.38 | -- |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 6.81 | 12.74 | 8.72 | 20.84 | 16.56 |
| Quick ratioi | 6.57 | 12.48 | 8.61 | 20.65 | 16.42 |
| Debt / assetsi | 5.13 | 4.29 | 7.30 | 4.24 | 3.80 |
| LT debt / equityi | -- | -- | 7.19 | 3.27 | 2.74 |
| Interest coveragei | -- | -27,593.50 | -3,025.42 | -6,261.00 | -18,069.20 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -34.97 | -39.41 | -42.25 | -31.41 | -37.25 | -45.32 |
| ROA %i | -31.67 | -35.38 | -37.67 | -28.94 | -34.10 | -41.02 |
| ROIC %i | -36.69 | -41.41 | -44.91 | -33.94 | -39.53 | -47.20 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -8,741.51 | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.03 | 18.07 | 18.39 | 16.56 | 13.08 | 10.64 |
| Quick ratioi | 20.80 | 17.86 | 18.10 | 16.42 | 12.90 | 10.50 |
| Debt / assetsi | 4.30 | 4.32 | 3.92 | 3.80 | 3.63 | 3.58 |
| LT debt / equityi | 3.21 | 3.14 | 2.84 | 2.74 | 2.73 | 2.64 |
| Interest coveragei | -7,350.82 | -10,548.25 | -14,187.33 | -18,069.20 | -32,878.33 | -37,035.67 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
United States100.00%
Quote time 2026-10-08 09:19:45 · For reference only, not investment advice and not tailored to your situation.